Entering text into the input field will update the search result below

Injectable Drug Delivery Market - Global Leaders & Growth Strategies Adopted By Them

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Increase In Demand for Biosimilar and Generic Injectables.
  • Contraceptive Injectables.

Recent Developments in the Global Injectable Drug Delivery Market:

In 2016, Gerresheimer extended its partnership with Taisei Medical Co. Ltd. (Japan) with an aim to market its ClearJect syringes and provide technical support to its customers. Furthermore, in collaboration with Taisei Medical, the company intends to expand its COP syringe portfolio by manufacturing a new Gx RTF ClearJect brand by combining ClearJect with its glass RTF (ready-to-fill) concept. This partnership is expected to help the company expand its product portfolio and customer base in the syringes market.

In 2015, Eli Lilly and Company and Sanford-Burnham Medical Research Institute (U.S.) entered into a collaboration for the development of immunological therapies focusing on lupus, Sjögren's syndrome, inflammatory bowel disease, and other autoimmune disorders. This collaboration will combine the expertise of both organizations to develop novel treatments for these diseases.

In 2014, Terumo Corporation collaborated with Ypsomed Group (a Switzerland-based injection systems manufacturer). Through this collaboration, the company integrated its prefillable polymer syringe, namely, PLAJEX with YpsoMate (an autoinjector system from Ypsomed). This helped the company strengthen its product offerings in the syringes market.

Global Leaders:

The leading players in the market are Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan).

Download PDF Brochure @ Injectable Drug Delivery Market

What the Market Looks Like?

The Injectable Drug Delivery Market is projected to reach USD 902.3 billion by 2027 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period.

For estimating the size of the injectable drug delivery market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each segment (Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, and Regions). The injectable drug delivery market size was derived by adding the markets of all these segments. The total market derived through the bottom-up approach was again validated through secondary sources and interviews.

Different Growth Strategies Adopted by Key Players:

Companies are focused on organic strategies such as product launches. This strategy helped the market players to build a strong position in the market, which helped in increasing demand of customers and to expand their presence in the global market.

The overall growth strategies adopted from 2013 to 2016 includes acquisition, agreements, collaboration, contracts, expansions, product launches, and partnerships. Companies adopted product launches and approvals to strengthen their customer base. Major players, namely, Becton, Dickinson and Company (U.S.), Baxter International (U.S.), Pfizer (U.S.), Gerresheimer AG (Germany), Schott AG (Germany), Eli Lilly and Company (U.S.), and Terumo Corporation (Japan) adopted product launches and approvals to expand their customer base and strengthen their position in the market.

Request Sample Pages@ Injectable Drug Delivery Market

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.